Shares of Amarin (AMRN -20.5%) are getting hammered this morning on the back of yesterday's announcement that it was raising funds and will begin hiring a sales force to independently launch Vascepa. The news disappointed investors who had hoped the biotech would have a partner by now. The company has already undertaken extensive preparations to launch the drug, but had held off on the costly move of hiring its own sales staff.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Wed, 8:45AM)
at Zacks.com (Mon, 9:13AM)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Feb 28, 2014)
at MarketWatch.com (Jan 21, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs